Drugs / 64Cu-SAR-BBN
64Cu-SAR-BBN
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05633160 | Jun 2023 → Apr 2025 | prostate carcinoma | Clarity Pharmaceuticals Ltd | Terminated | No outcome recorded Stop: Business |
| Phase 22 trials | ||||||
| Phase 2 | NCT05407311 | Sep 2022 → May 2024 | prostate carcinoma | Clarity Pharmaceuticals Ltd | Completed | No outcome recorded |
| Phase 2 | NCT05613842 | Aug 2022 → Jun 2023 | prostate cancer | St Vincent's Hospital, Sydney | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 64Cu-SAR-BBN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05633160 ↗ |
| Known as | Copper-64 labelled SAR-Bombesin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05613842 ↗ |
| Known as | SAR-BBN CU-64 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5316161 ↗ |
| Modality | Diagnostic / imaging agent | “64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer” NCT05407311 ↗ |